LYSOCLEAR

Lysoclear is a recombinant enzyme product under development by Ichor Therapeutics that is able to selectively localize to the lysosomes of RPE cells where toxic vitamin A aggregates accumulate, and destroy them... Lysoclear, Inc. is a pre-clinical Ichor Therapeutics portfolio company that develops enzyme therapies for eye disease. The company is currently developing leads to treat atrophic "dry" age-related macular degeneration and Stargardt's macular degeneration... Lysoclear operates identically to existing LSD therapies. However, instead of replacing a defective enzyme, a new enzyme is introduced that upgrades RPE cells with the ability to degrade A2E and other lipofuscin components.

Also known as: Lysoclear, Inc.